Table 1:
Baseline characteristics of the study cohort
| No AS (n = 43) | Sclerosis (n = 9) | Mild (n= 25) | Moderate/severe (n = 9) | p value | |
|---|---|---|---|---|---|
| Age | 70 (60– 78) | 68 (59– 76) | 71 (67– 79) | 75 (72– 85) | 0.02 |
| Female | 26 (60) | 6 (67) | 13 (52) | 5 (56) | 0.49 |
| HTN | 41 (95) | 8 (89) | 24 (96) | 9 (100) | 1.00 |
| DM | 24 (56) | 3 (33) | 15 (60) | 5 (56) | 0.82 |
| CAD* | 20 (47) | 3 (33) | 10 (40) | 3 (33) | 0.21 |
| Medications | |||||
| BB | 34 (79) | 6 (67) | 20 (80) | 6 (67) | 0.59 |
| CCB | 14 (33) | 2 (22) | 10 (40) | 4 (44) | 0.81 |
| ACE inhibitor | 22 (51) | 4 (44) | 13 (52) | 3 (33) | 0.64 |
| Aspirin | 28 (65) | 5 (56) | 17 (68) | 4 (44) | 0.64 |
| Statin | 34 (79) | 7 (78) | 20 (80) | 7 (78) | 1.00 |
| Systemic hemodynamics | |||||
| Resting HR | 66 (60– 74) | 66 (59– 76) | 68 (59– 73) | 68 (60–80) | 0.77 |
| Resting SBP | 152 (127– 166) | 137 (126– 158) | 156 (132– 168) | 134 (129–145) | 0.93 |
| Resting DBP | 69 (61– 77) | 71 (62– 74) | 71 (62–81) | 67 (55–75) | 0.53 |
| Resting MAP | 101 (84– 104) | 93 (86– 108) | 96 (86– 109) | 91 (81–99) | 0.69 |
| Resting RPP | 9540 (8400– 11590) | 8800 (7906– 12008) | 9636 (8880– 11970) | 8700 (8305–9360) | 0.83 |
| Peak HR | 77 (68– 87) | 79 (63– 90) | 77 (66– 89) | 88 (70–120) | 0.63 |
| Peak SBP | 136 (117– 155) | 116 (114– 143) | 150 (136– 162) | 126 (124– 129) | 0.92 |
| Peak DBP | 63 (57– 71) | 61 (54– 65) | 67 (61–76) | 59 (56– 60) | 0.52 |
| Peak MAP | 87 (77– 103) | 81 (70–91) | 96 (82– 103) | 81 (80–83) | 0.42 |
| Peak RPP | 10413 (8540–12690) | 9120 (7268– 11880) | 11340 (9000– 13760) | 10472 (8308– 15120) | 0.67 |
Values are median with interquartile range or n (%).
*
CAD if history of MI, PCI or CABG.
BB= beta blocker; CBB= calcium channel blocker; ACE= angiotensin converting enzyme; HR= heart rate; SBP= systolic blood pressure; DBP= diastolic blood pressure; MAP= mean arterial pressure; RPP= rate pressure product defined as HR × SBP
HR in bpm; SBP, DBP, MAP in mmHg